AtriCure (ATRC) UBS Global Healthcare Conference summary

Key business performance and product updates

• Q3 saw accelerated growth across franchises, with standout performance in pain management and open AtriClip segments, supported by new product launches and robust U.S. open ablation growth.

• EnCompass Clamp continues to drive growth in open ablation, and FLEX-Mini launch is building excitement and market penetration.

• Full-year effects of recent product launches, including cryoSPHERE MAX and FLEX-Mini, are expected to support growth in 2025, with ASP uplifts contributing to revenue.

• International expansion includes EnCompass Clamp clearance in Europe and AtriClip approval in China, with contributions expected in late 2025.

• Pressure in the MIS business is anticipated to continue into 2025 due to new PFA technologies, with headwinds strongest in the first half.

Competitive landscape and market dynamics

• Competitive trialing in the AtriClip business is waning, with most accounts reaffirming preference for AtriClip after trials.

• The main competitive threat is in the open chest segment, but not all revenue is at risk; competitor's product is priced higher.

• Both AtriClip and its competitor are growing, with market validation from new entrants helping overall market expansion.

• Real-world experience and extensive data support AtriClip's competitive moat, especially in Europe with recent label expansion.

• The company is preparing for long-term competition, viewing new entrants as permanent market players.

Profitability, investment, and capital deployment

• Continued high investment in R&D, with LeAAPS trial enrollment expected to complete in 2025 and spend leveling off thereafter.

• Focus on leveraging SG&A, improving commercial efficiency, and scaling administrative functions to benefit margins.

• High gross margins are maintained, but international expansion presents margin headwinds; new product development and manufacturing efficiencies are targeted for improvement.

• Differentiated innovation enables double-digit price uplifts on new products, with FLEX-Mini commanding a 30% premium over FLEX-V.

• Capital deployment will prioritize organic growth through R&D and clinical trials, with ongoing evaluation of market expansion opportunities.